We report the design and synthesis of an aquacarbonyl Ru(II) dication The chemical re-design of native protein scaffolds as artificial metalloproteins through the attachment of organometallic moieties offers tantalising opportunities not only in (bio)catalysis 1-5 but also for the delivery of organometallic-based drugs. 6 In one example, an artificial metallohydrolase featuring two different metal ions, Zn(II) and Hg(II), which are required for catalysis and structural stability, respectively, was shown to catalyse p-nitrophenyl acetate ( pNPA) hydrolysis with an efficiency comparable to that of human carbonic anhydrase (CA)-II and much higher than similar synthetic complexes. 7 In another example, a bifunctional artificial streptavidin metalloenzyme, displaying both an engineered carboxylate side-chain and a docked biotinylated rhodium(III) complex, enabled catalytic asymmetric C-H activation. 8 In addition to catalysis, artificial metalloproteins have also shown promise for the in vivo delivery of organometallic-based drugs. For example, Pt(IV) prodrugs have been designed to specifically bind in a non-covalent manner to human serum albumin (HSA) as a delivery vehicle, enhancing significantly its stability in whole human blood.
The chemical re-design of native protein scaffolds as artificial metalloproteins through the attachment of organometallic moieties offers tantalising opportunities not only in (bio)catalysis [1] [2] [3] [4] [5] but also for the delivery of organometallic-based drugs. 6 In one example, an artificial metallohydrolase featuring two different metal ions, Zn(II) and Hg(II), which are required for catalysis and structural stability, respectively, was shown to catalyse p-nitrophenyl acetate ( pNPA) hydrolysis with an efficiency comparable to that of human carbonic anhydrase (CA)-II and much higher than similar synthetic complexes. 7 In another example, a bifunctional artificial streptavidin metalloenzyme, displaying both an engineered carboxylate side-chain and a docked biotinylated rhodium(III) complex, enabled catalytic asymmetric C-H activation. 8 In addition to catalysis, artificial metalloproteins have also shown promise for the in vivo delivery of organometallic-based drugs. For example, Pt(IV) prodrugs have been designed to specifically bind in a non-covalent manner to human serum albumin (HSA) as a delivery vehicle, enhancing significantly its stability in whole human blood. 9 Anchoring of a non-native organometallic moiety into a protein template is a challenging task and it is usually achieved using dative, covalent or supramolecular strategies. 4, 5 Among these, covalent modification of cysteine (Cys) residues with complexes bearing reactive electrophilic handles (namely prosthetics) has received considerable attention. [1] [2] [3] [4] [5] Cys bioconjugation with a-haloacetamide functionalised complexes has been used to create, for example, an artificial Diels-Alderase 10 and an artificial metalloenzyme for olefin metathesis. 11 While the covalent conjugation of metal complexes equipped with reactive handles to nucleophilic side chains on proteins has been already demonstrated, the direct metallation of a native or non-native pre-determined site on a protein scaffold by creating a stable side chain-metal bond is less common. In this context, the non-selective metallation of histidine (His), a privileged metallophile residue, has been exploited in coordination-based protein modification strategies 12 using the nickel(Ni)(II)-His-tag pair 13 as well as in other metallation reactions with cobalt (Co) 14 and ruthenium (Ru) complexes. 15 Unlike these remarkable examples, His-selective metallation of proteins leading to stable, fully functional materials is to the best of our knowledge unprecedented. Alternatively, one could consider employing genetic encoding methods to introduce an unnatural amino acid with a designer side chain for metal binding. This approach has been recently utilized by Roelfes and co-workers to create an artificial metalloprotein for catalytic asymmetric Friedel-Crafts alkylation reactions. 16 We have previously described the interactions of the Ru carbonyl complex [ fac-RuCl(k . 17 This fragment is likely to arise from the hydrolytic decomposition of CORM-3 in aqueous solution through a watergas shift reaction (Fig. S1 , ESI †). 19, 20 As a protein scaffold we chose the CXC chemokine interleukin-8 (IL-8), which is associated with the promotion of neutrophil chemotaxis and degranulation upon inflammatory stimuli. IL-8 activates multiple intracellular signalling pathways downstream of two G protein-coupled receptors (CXCR1 and CXCR2), and over-expression of IL-8 and/or its receptors has been described in cancer and endothelial cells, infiltrating neutrophils and tumour-associated macrophages, demonstrating the key roles of IL-8 as a regulatory factor within the tumour microenvironment. 22 Structurally, IL-8 features two His residues, His18 and His 33, that in solution display lower pK a values (3.7 and 4.9, respectively) than His usually does (pK a B 6.0). [23] [24] [25] The unique reactivity of each of the His residues present in IL-8 makes it an ideal scaffold to achieve His-selective metallation with the cis-[Ru(CO) 2 ] 2+ fragment.
We began by synthesising the aquacarbonyl Ru(II) dication cis-[Ru(CO) 2 modification at His33, which was further corroborated in the MS/MS spectrum (Fig. S5, ESI †) . No modification could be found at His18, demonstrating that His33 is the primary site of metallation. Interestingly, this result also shows that the His-Ru bond is stable under processing/analysis conditions similar to other His-Ru complexes. 15 The stability of the present site-and residue (His)-selective strategy opens up the development of orthogonal double His modification protocols for the installation of dual labels that will ensure probe homogeneity unlike other nonselective metallation protocols. Having shown that it is possible to achieve selective metallation of His33 in IL-8, we next studied whether the new artificial chemically defined metalloproteins could spontaneously release one CO ligand from the introduced cis-[Ru(CO) 2 ] 2+ motif. Our group is interested in innovative methods for the in vivo delivery of therapeutic CO 6, 28 and has recently demonstrated that Ru II (CO) 2 -albumin complexes are able to carry and release CO in aqueous solution, live cells and mice. 21 The viability of HeLa cells in the presence of the artificial IL-8-Ru II (CO) 2 metalloprotein ( Fig. 2A) was (Fig. 2B) . Using this assay, we could visualize cytosolic CO release (associated with COP-1 staining), which seems to be intensely associated with the perinuclear region (Fig. 2C) , in accordance to what we previously reported. 21 Interpreted as a whole, these data further corroborate the benefits associated with the use of protein scaffolds for carrying and delivering CO. IL-8 is a chemokine produced and secreted by macrophages and other cell-types including epithelial cells. In addition to its role as a promoter of angiogenesis in humans, 22 IL-8 acts mainly as a chemotactic factor, by inducing migration of neutrophils and other granulocytes towards infection sites. To assess if IL-8 retained its chemotactic activity when conjugated to the cis-[Ru(CO) 2 ] 2+ motif, a neutrophil migration assay was performed, using human neutrophils isolated from freshly collected blood. Neutrophil migration induced by the artificial metalloprotein IL-8-Ru II (CO) 2 was compared against that which native IL-8 can induce. In the migration assay, IL-8-Ru II (CO) 2 was able to decrease neutrophil retention in the Transwell membrane at similar levels to those induced by IL-8 alone, i.e. both unmodified and modified IL-8 increase neutrophil migration (Fig. 3) . Previous modification of IL-8 by introduction of the natural posttranslational modification citrullination had led to a considerable reduction in chemotactic activity. 30 . In addition, we were able to show that CO can spontaneously be released from the new artificial metalloprotein, both in aqueous solution and live cells. Importantly, the use of IL-8 as a scaffold for the engineering of a new artificial metalloprotein did not alter the protein's activity leading to a novel, fully functional material. In the case of IL-8 neither the introduction of the Ru moiety nor the CO released impacted IL-8's neutrophil chemotactic activity. Overall we expect that the exquisite His discrimination presented herein will establish the basis to precisely understand the roles of different metallation sites in CO delivery using proteins and hopefully pave the way towards the development of artificial metalloproteins for the safe and controlled delivery of therapeutic CO.
We 2 or CORM-3 (50 equivalents) was added as a solid to the protein solution (1 mL, c = 1.0 mg mL À1 ) in PBS pH 7.4 in a plastic tube and the mixture was vortexed to homogenize. The reaction was maintained for 30 min at room temperature. Purification of the metallated protein was achieved by size exclusion chromatography using a HiTrap desalting column (GE Healthcare) to remove excess reagents. Purified samples were used for mass spectrometry analysis under the conditions described in the ESI. †
